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Introduction
Gastric cancer is the second leading cause of death from cancer worldwide and accounts for nearly one in ten of all cancer deaths (1) . Most new cases and deaths occur in East Asian countries, including China, Japan and Korea (2) . Such high incidence rates in this region may be due in part to the preference for a high-salt diet, a high proportion of smokers and a high prevalence of helicobacter pylori infection (2, 3) . Despite advances in diagnostic methods and improvement of both surgical skills and systematic chemotherapy regimens, the overall prognosis for gastric cancer remains disappointing, especially for those with late-stage disease; the 5-year survival rate for patients with stage III/IV metastatic gastric cancer is only around 10% (4, 5) . Better management of this disease, particularly through the use of targeted therapeutic agents, is required.
Genetic abnormality and intra-tumor heterogeneity are two typical features of cancer cells which play crucial roles in carcinogenesis and tumor progression (6) . Although detailed mechanisms of tumor development driven by gene amplification, mutation or translocation have not been fully characterized (7) , aberrant genes have been demonstrated clinically as valid targets for cancer treatment (8) (9) (10) . A key challenge that remains, however, is how to distinguish these so-called 'driver' oncogenes from other co-existing 'passenger' genes (11) . In order to facilitate the identification and validation of 'driver' genes, patient-derived specimen-based molecular analysis techniques and in vivo disease models have been widely employed (12) (13) (14) .
Consequently, a number of candidate oncogenes, including several within the receptor tyrosine kinase (RTK)/RAS pathway, have been discovered in gastric cancers (15, 16) . Genetic modifications or over-expression of FGFRs have been associated with tumorigenesis and progression in breast, prostate, stomach and hematological malignancies (21, 22) . In particular, abnormal activation of FGFR2 signaling has been linked with several types of human cancers, and somatic FGFR2 mutations have been reported in lung, gastric and ovarian cancers (23) (24) (25) . FGFR2 amplification has been associated with tumor cell proliferation and survival of gastric cancer cell lines (26) . Furthermore, FGFR2 amplification may correlate with a poor prognosis for gastric cancer patients (27) . Thus, FGFR2 has attracted significant attention as a potential therapeutic candidate for the development of targeted therapeutic anticancer agents (28) .
AZD4547 is an orally bioavailable, highly selective and potent ATP-competitive small-molecule tyrosine kinase inhibitor of FGFR1-3. We have previously described the chemical structure and selectivity profile of this compound and shown that it can significantly inhibit FGFR phosphorylation and repress proliferation of cancer cell lines via inhibition of FGFR signaling (29) . AZD4547 treatment has also exhibited antitumor activity in a representative FGFR-driven human tumor xenograft model.
Currently, the compound is under investigation in several Phase I and II clinical trials (ClinicalTrials.gov identifiers: NCT01202591; NCT01457846; NCT00979134; NCT01213160).
In the current study, amplification of the FGFR2 gene was identified in a subset of Chinese and Caucasian gastric cancer patients. Subsequently, we aimed to investigate the preclinical activity of AZD4547 in FGFR2-amplified gastric cancer models and ultimately demonstrated potent antitumor activity with tumor regression selectively occurring in FGFR2-amplified gastric cancer xenografts.
Research. 
Materials and methods

Materials
The following chemical reagents were all obtained from Sigma-Aldrich: cisplatin (Cat# P4394), fluorouracil (Cat# F6627), docetaxel (Cat# 01885) and irinotecan (Cat# I1406).
The following antibodies were purchased from Cell Signaling Technology (CST):
phospho-FGFR2 (tyr653/654), phospho-FRS2α (tyr436), phospho-PLCγ 1 (Tyr783), phospho-p44/p42 MAP kinase (Erk1/2), total-Erk, phospho-S6 (ser240/244), total-S6, and 2mM L-glutamine (Invitrogen). All cell lines were genetically tested and authenticated using the StemElite ID TM System Kit (Promega, #G9530) and were not cultured for more than 3 months prior to performing the work described here.
Female Balb/c nude mice aged 6-8 weeks old and 8-10 week old female (nu/nu) SCID nude mice were purchased from Vital River, Beijing, China. Animals were housed in a specific pathogen-free animal facility in accordance with the Guide for Care and Use of Laboratory Animals (Eighth edition) and the regulations of the Institutional Animal Care and Use Committee (IACUC). All animal studies were approved by the IACUC committee.
All studies using human tissues were performed with the patients' consent and the approval of the Local Research Ethics committee.
Research. Array comparative genomic hybridization (aCGH) analysis of gastric cancer patient samples FGFR2 gene copy number was analyzed in frozen patient tissue samples using the Agilent 244K array CGH platform. The quality of the raw data was checked with Agilent CGH Analytics software, using the derivative of the log ratio spread (DLRSpread) as a surrogate for assay quality. Any sample with a DLRSpread >0.3 was excluded from further analysis. Data for those samples that qualified for further assessment were subsequently analyzed using Nexus software (version 4) for recovery of FGFR2 segmental structure (segmentation) and the discrete copy number value at the single-sample level (calling). Segments with an array CGH logRatio (copy number of sample versus control) >0.8, were classified as amplified.
Fluorescence in situ hybridization (FISH) analysis
The FGFR2 FISH probe was generated from BAC (RP11-62L18) DNA directly labeled with Spectrum Red (ENZO, #02N34-50). The Spectrum Green-labeled centromere of chromosome 10 (CEP10) probe (Vysis #32-132010) was used as an internal control. FISH analysis was performed according to routine methodology (30) .
In brief, 4 μm sections from formalin fixed and paraffin embedded (FFPE) gastric cancer patient tissue samples were deparaffinized. After pretreatment with the SpotLight Tissue pretreatment kit (Invitrogen, #00-8401), tissue sections and the FGFR2/CEP10 probes were denatured at 80°C for 5 minutes, and then incubated together at 37°C for 48 hours. Following this hybridization step, excess and unbound probes were removed with post-hybridization wash buffer (0.3% NP40/1xSSC at 75.5°C for 5 minutes followed by two washes of 2xSSC at room temperature for 2 minutes), and nuclei were counterstained with DAPI (4', 6 diamidino-2-phenylindole). 
Immunohistochemistry
Immunohistochemical (IHC) analysis was performed using a Lab Vision autostainer.
In brief, 3 μm formalin fixed paraffin embedded (FFPE) sections were dewaxed and rehydrated on the Leica XL autostainer and underwent antigen retrieval for 5 minutes in pH 6 retrieval buffer (S1699; DAKO) followed by washing in running tap water for 5 minutes. Sections were rinsed in Tween-Tris buffered saline (TBST) and Membranes were re-probed to assess total-Erk1/2 (SCT #4960) and total-S6 levels (CST #2317; 1:1000).
In vitro cell-cycle analysis study
SNU-16 cells were exposed to AZD4547 0 (DMSO control Once the volume of the tumor xenograft reached approximately 300-500 mm 3 , it was excised and cut into approximately 2 mm 3 segments, which were further implanted subcutaneously via Trocar needle into nude mice.
PDGCX mouse models were generated using tumor tissue from Chinese gastric cancer patients. In brief, surgically excised tumor tissue (F0) was cut into approximately 2 mm 3 segments and implanted s.c. into immune-compromised nude mice or SCID mice (F1). Transplantation occurred within 2 hours following excision.
Subsequent passages were made into additional nude mice once the grafted tumors had reached a size of 400-600 mm 3 . PDGCX models within ten passages (between F3 to F10) were used to evaluate antitumor efficacy.
For all in vivo studies, tumors were measured in two dimensions with calipers and the tumor volume was calculated using the following formula: tumor volume = (length x width 2 ) x 0.5.
In vivo antitumor efficacy studies
SNU-16 xenograft model and PDGCX mouse models were used to study the The PDGCX-based PD study was performed on xenograft tissue samples derived from animals treated as part of the AZD4547 efficacy study. Mice that had previously been administered AZD4547 1.56 mg/kg/qd during the efficacy study were given a single dose of AZD4547 12.5 mg/kg. Two hours post dose, xenograft tissue samples were collected and formalin-fixed sections were probed for phospho-Erk and phospho-S6 levels using IHC methods described earlier.
Inducible shRNA knockdown of FGFR2 in vitro and in vivo
A construct containing FGFR2-specific (exon 17) shRNA sequence under the control of the tetracycline promoter was used for this study. The shRNA sequences were 2B: GAATGAAGAACACGACCAA and 3C: GACTTGGATCGAATTCTCA (Invitrogen).
SNU-16 cells were transfected with the FGFR2 construct and stable clones were selected using the antibiotic Puromycin (Sigma-Aldrich, P9620). A construct containing enhanced green fluorescent protein (EGFP)-specific shRNA sequence was used as a control, in which expression of shRNA can be induced by doxycycline (Sigma-Aldrich, D9891). SNU-16 parental cells and four stable clones (SNU-16_sh-EGFP control, SNU-16_sh-FGFR2 2B and SNU-16_sh-FGFR2 3C6 and 3C8) were established and used for the FGFR2 knockdown studies.
For the in vitro study, SNU-16 cells were treated with doxycycline 1 µg/ml for 1, 2 or 4 days, and the levels of FGFR2, phospho-FGFR and cleaved caspase-3 in the cell lysates were determined by Western blot analysis. 
Results
FGFR2 is genetically amplified in tumor samples from patients with gastric cancer
Tumor samples for array CGH analysis were provided by the Beijing Cancer Hospital.
Eligible samples (tumor content of ≥70%) were collected from 131 Chinese patients with gastric cancer; the median age of the patients was 62 years (range 34-81) and the majority were male (n=94; 71%). Twenty age-matched tumor-free samples were used as control tissue. Amplification of the FGFR2 gene was identified in three (2%) of the 131 samples analyzed (Fig 1A) . FGFR2-amplified) , showed insensitivity to AZD4547 with GI 50 values ranging from 1.6 to 30 μM (Fig 2A) . 
clones were generated and tested in an in vitro proliferation assay. FGFR2 knockdown potently inhibited the growth of SNU-16 gastric cancer cells in vitro ( Fig   2B) . Following transfection with the construct incorporating FGFR2 clone 3C8, total-FGFR2 levels were reduced in a time-dependent manner following doxycycline treatment, with phospho-FGFR2 being undetectable after 1 day. Importantly, cleaved caspase-3 levels were substantially increased under the same conditions (Fig 2C) .
In contrast, both total-and phospho-FGFR2 were increased in parental or EGFP (vector control) transfected SNU-16 cells after doxycycline treatment (Fig 2C) .
Similar results were obtained with the control clone 3C6 (data not shown).
Following incubation with 30 nM AZD4547, levels of phosphorylated FGFR2 and its downstream signaling molecules; PLCγ, FRS2, pErk1/2 and S6 were all reduced in SNU-16 cells and similar modulation of these phospho-markers was observed in the KATOIII cell line (Fig 2D) . Furthermore, dose-dependent increases in sub-G1 population of SNU-16 cells were also detected at 48 hours post-AZD4547 treatment (Fig 2E) .
FGFR2 inhibition leads to tumor regression in SNU-16 xenografts in vivo
To extend the findings above, stable SNU-16 cell tet-controlled FGFR2 expression clones were used in in vivo studies. Doxycycline treatment of mice harboring established SNU-16 xenografts led to tumor regression only in those tumors stably expressing tet-controlled FGFR2 shRNA (clones 3C8 or 2B; Fig 3A) . Tumor regrowth was observed following cessation of doxycycline treatment (Fig 3A) .
Similarly, treatment of mice harboring FGFR2-amplified SNU-16 cells with AZD4547 over a 25-day period resulted in dose-dependent tumor growth inhibition, with significant tumor regression achieved using a daily dose of 12.5 mg/kg AZD4547 (Fig 3B) .
To assess PD effects, mice bearing SNU-16 xenografts were treated with a single oral dose of 12.5 mg/kg AZD4547. Two hours post dose, greater than 95% inhibition of tumor FGFR2 phosphorylation was achieved, with partial recovery observed by Western blot at 24 hours (Fig 3C) . Using both Western blot and IHC approaches, levels of the downstream markers phospho-ERK and phospho-PLCγ were suppressed by ≥90% at 10 hours, with partial recovery apparent by 24 hours post dose (Fig 3D) . The overall total plasma concentration of AZD4547 that was required to maintain 24-hour coverage of phospho-FGFR modulation correlated well with the AZD4547 concentration required for 90% inhibition (IC 90, 50 nM) of SNU-16 cell growth in an in vitro anti-proliferation assay. In addition, 50% inhibition of phosphoErk and phospho-PLCγ was also observed at the AZD4547 IC 90 (50 nM) concentration in the SNU-16 PK/PD tumor xenograft model (Fig 3D) .
Importantly, AZD4547 treatment led to a significant reduction in the proportion of SNU-16 tumor xenograft cells staining positive for Ki-67 and an increase in those positive for apoptotic markers (Fig 3E) .
AZD4547 induces tumor regressions in a PDGCX model carrying FGFR2 amplification
To extend the translational relevance of our findings, we next sought to identify and test AZD4547 in a relevant PDGCX model. FISH analysis identified the patientderived gastric cancer xenograft model, SGC083, as being FGFR2-amplified.
Antitumor efficacy studies confirmed this model to be highly sensitive and dose responsive to AZD4547 treatment, with significant tumor regression achieved using a daily 6.25 mg/kg dose of AZD4547 and complete tumor regression (undetectable tumors) was observed at doses of 12.5 mg/kg and 25 mg/kg AZD4547 (Fig 4A) .
Moreover, using quantified IHC staining, significant modulation (p<0.05) of phosphoErk and phospho-S6 was demonstrated using a dose of 12.5 mg/kg AZD4547 ( Fig   4C) , thus confirming pathway modulation in vivo.
In contrast to the marked tumor regressions observed upon AZD4547 treatment of the FGFR2-amplified SNU-16 and SGC083 xenograft models, only minimal to partial tumor growth inhibition was observed in the AZ521, MGC803, G001 and G009 FGFR2 non-amplified gastric cancer xenograft models (Table 1) . Furthermore, treatment of the FGFR2 low polysomy model, G001, with 12.5 mg/kg AZD4547 did not result in significant modulation of pFGFR, pFRS2 or pErk (data not shown).
Indeed, baseline expression of pFGFR2 and corresponding pathway activation were low or undetectable across the FGFR2 non-amplified models we tested (data not shown).
To investigate the durability of the AZD4547 antitumor effect, mice bearing established SGC083 tumors were treated with 12.5 mg/kg AZD4547 for 20 days, at which point full tumor regression was achieved. Of seven mice, four were still tumor free at Day 116 when measurements were stopped. Three mice began to show tumor regrowth around Day 35, thus providing the opportunity for drug rechallenge.
One mouse (SGC083F5-007) was rechallenged with 12.5 mg/kg AZD4547 at day 48, and complete regression was re-established after a further 20 days of treatment ( Fig   4D) .
Combined treatment with AZD4547 enhances the antitumor efficacy of cytotoxic agents in the FGFR2-amplified SNU-16 xenograft model
In order to assess the effects of combining AZD4547 treatment with existing standard of care chemotherapies, the SNU-16 xenograft model was tested preclinically with 5-Fluorouracil(10 mg/kg/qd)/Cisplatin(4 mg/kg/qw) (FC) and a low dose of AZD4547(3.1 mg/kg/qd). Single agent FC or AZD4547 gave tumor growth inhibition (TGI) values of 25% and 34% respectively, whilst 68% TGI was achieved when the same doses of AZD4547 and FC were combined (Fig 5A) . Similar results were observed when AZD4547 was combined with either docetaxel or irinotecan.
Single-agent docetaxel treatment achieved 48% TGI, whilst the combination with AZD4547 resulted in approximately 82% TGI. Monotherapy usage of irinotecan or AZD4547 generated TGI values of 60% and 14% respectively, whilst the combination resulted in significant tumor regression (100% TGI) (Fig 5B) . The combination regimens were well tolerated as determined by minimal body weight loss (data not shown).
Research. (31) (32) (33) and FGFR3 mutation has been identified in bladder cancer (34) . FGFR2 genetic mutation or amplification leads to abnormal activation of the FGFR2 signaling pathway and contributes to carcinogenesis and tumor development in melanoma and gastric cancers, respectively (35) (36) (37) (38) . In this study, we report FGFR2 gene amplification incidence rates of 4.5% and 7% in cohorts of Chinese and Caucasian gastric cancer patients, respectively, consistent with previously published reports (36, 37) . Interestingly, FGFR2 amplification was found to be mutually exclusive with HER2 and c-MET amplifications in these patient samples (data not shown). Thus, our data confirms the presence of a distinct segment of gastric cancer patients harboring tumors molecularly characterized by Compared with standard cell-line derived tumor xenografts, patient-derived gastric cancer xenograft models offer the benefits of more informative disease models through maintenance of tumor heterogeneity and preservation of tumor architecture.
Importantly, the FGFR2 amplification status was maintained between the patientderived gastric cancer xenograft (PDGCX) models used and the original patient tumor samples from which they were derived (data not shown). Interestingly, we were able to perform some limited investigation of the rates and durability of complete tumor regression using the PDGCX model, SGC083. Following once-daily dosing of 12.5 mg/kg AZD4547, all seven mice showed complete regression of tumors within 3 weeks, and importantly, four of the mice were still tumor free at the end of the study on Day 116. Of the three tumors which regrew, one was rechallenged with AZD4547 and regression re-established, indicating that the tumor 
remained sensitive to FGFR2 inhibition and that FGFR2 was likely still the 'driver' oncogene within this tumor. To our knowledge, this is the first observation of a FGFR2-amplified PDGCX tumor model showing such robust and durable antitumor response to a targeted pharmacological agent. Taken together, the studies above demonstrate that FGFR2 amplification leads to constitutive activation of the FGFR2 signaling pathway in gastric cancer, and furthermore that inhibition of this pathway using a well-tolerated, potent and selective inhibitor can lead to rapid and durable tumor regressions in FGFR2-amplified gastric cancer xenograft models.
In summary, our data demonstrates the existence of a cohort of Chinese and 
